AstraZeneca Prospero VIDA study - Accellacare

Project Overview

The AstraZeneca Prospero VIDA clinical study was designed to collect standardised, high-quality CT chest imaging data to support the development of respiratory medicines.

LivingCare was commissioned to deliver the imaging component of the study, ensuring all scans were performed in line with sponsor protocol, ethical approval and regulatory requirements.

Our Role

LivingCare delivered the end-to-end imaging pathway for the study, including participant booking, radiation risk assessment, low-dose CT chest imaging, anonymisation of imaging data, image reporting, and secure data transfer to the sponsor for central analysis.

All scans were performed using Siemens low-dose CT protocols, validated by a Medical Physics Expert (MPE) and aligned with AstraZeneca’s imaging requirements. A dedicated research IR(ME)R procedure was implemented to ensure full compliance with local and national regulations.

Imaging data were anonymised using unique study identifiers and transferred securely using encrypted systems before uploading to AstraZeneca’s VIDA imaging portal.

Outcomes

All imaging was delivered fully to protocol, with complete compliance against sponsor, ethical and governance requirements. Imaging data were transferred securely and successfully for central review, supporting the study’s research objectives.

Following completion, post-study audit confirmed full adherence to data security and governance standards, with positive feedback received on responsiveness, documentation accuracy and delivery quality.

• Strong compliance with sponsor protocols and IR(ME)R regulations
• Secure, auditable handling and transfer of imaging data
• Rapid resolution of technical and system compatibility challenges
• Effective collaboration with sponsor, research partner and IT teams
• Flexible and resilient delivery in a highly regulated research environment